Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Mitobridge Acquisition Completed: Astellas
January 25, 2018
- Swiss Regulator Accepts Edaravone for ALS: Mitsubishi Tanabe
January 24, 2018
- Miraca Inks Exclusive Service Accord with Myriad for Lynparza CDx
January 24, 2018
- Opdivo Earns Gastric Cancer Nod in Taiwan
January 24, 2018
- Adcetris Adds CTCL Indication in Europe
January 24, 2018
- Gilteritinib Grabs EU Orphan Status for AML: Astellas
January 24, 2018
- Biogen Japan to Kick Off PIII Study for Stroke Drug by Year-End
January 24, 2018
- Mitsubishi Tanabe Withdraws Patent Infringement Lawsuit over Radicut Bag against Nissin Pharmaceutical
January 24, 2018
- AnGes’ Gene Therapy Re-Submitted for CLI, This Time for Conditional Approval
January 23, 2018
- Astellas/Vical’s CMV Vaccine Flops in Global PIII
January 23, 2018
- MSD Files for Once-Daily Isentress in Japan
January 23, 2018
- Huahai’s Japan Arm to Focus on Sales of API, Contract Manufacturing; Planning Sales of In-House Products in 10 Years
January 23, 2018
- Eisai Grants Rights for Cancer Agent E7046 to Chinese Immunotherapy Firm
January 22, 2018
- Mochida’s Enbrel Biosimilar Approved, with Ayumi as Distributor
January 22, 2018
- US Court Rejects Eisai Partner’s Bid for Rehearing on Aloxi Decision
January 19, 2018
- NanoCarrier in Talks for Biz Alliance with Ceolia
January 19, 2018
- Industry Expresses Disappointment about “Expansion” of Essential Drugs; Some Looking to Real Expansion in FY2020
January 19, 2018
- Japan Units of Shire, Baxalta to Merge on Feb. 1
January 19, 2018
- Another Drug Lag “Will” Arise, Says Mitsubishi Tanabe President after JPMA Chief’s Denial
January 19, 2018
- Novartis to Transfer Rasilez to OrphanPacific in Japan
January 18, 2018
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…